More importantly, the present study further validates the neuroprotective effects of targeting the neurotoxic NH2htau in vivo by non-invasive delivery of the cleavage-specific anti-tau 12A12mAb, pointing out its safe use for the medical treatment of AD. Here, MAPT is linked to Alzheimer disease.